Company intelligence / Profile preview

Human Life CORD

Chiyoda City, Tokyo, Japanhumanlifecord.com ↗

Ownership: Private
Employees: ~50
Development stage: Phase 1

Overview

Currently conducting clinical trials for umbilical cord-derived mesenchymal stromal cells therapy for COVID-19 related Acute Respiratory Distress Syndrome. One trial is recruiting (JPRN-JapicCTI-205465) and one is completed (JPRN-jRCT1080225369).

Therapeutic areas: PulmonologyRare Diseases
Modalities: Cell TherapyMesenchymal Stromal Cells (MSCs)
Industry: Biotech

Drug pipeline

5 assets

human umbilical cord derived mesenchymal stem cells

4 more assets in the full pipeline.

Request access →

Partnerships

Tissue GenesisNYBCe (New York Blood Center enterprises)

Beyond the preview

Go deeper on Human Life CORD.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Human Life CORD.

Explore the full profile